scholarly article | Q13442814 |
P50 | author | Kenneth A. Jacobson | Q37387267 |
Zhan-Guo Gao | Q89154457 | ||
P2860 | cites work | Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000 | Q21262008 |
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders | Q24605472 | ||
Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways | Q24646643 | ||
Allosteric modulation of metabotropic glutamate receptors | Q30448534 | ||
The use of AlphaScreen technology in HTS: current status | Q33531821 | ||
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 | ||
Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay | Q33976371 | ||
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy | Q34227284 | ||
Label-Free Receptor Assays | Q34473007 | ||
Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. | Q34719701 | ||
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers | Q35154034 | ||
Quantifying ligand bias at seven-transmembrane receptors. | Q35188090 | ||
Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor | Q35650779 | ||
Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. | Q35688485 | ||
Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry | Q35877911 | ||
Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). | Q36015452 | ||
A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. | Q36286214 | ||
Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor | Q36294407 | ||
Keynote review: allosterism in membrane receptors | Q36437496 | ||
Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery | Q36758566 | ||
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | Q37360436 | ||
Cellular assays as portals to seven-transmembrane receptor-based drug discovery | Q37553926 | ||
HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications | Q37693742 | ||
Label-free whole-cell assays: expanding the scope of GPCR screening | Q37769932 | ||
Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. | Q37803251 | ||
Functional selectivity of adenosine receptor ligands | Q37872220 | ||
Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay | Q38014554 | ||
Functional selectivity induced by mGlu₄ receptor positive allosteric modulation and concomitant activation of Gq coupled receptors | Q39378056 | ||
Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. | Q39419158 | ||
A 100K well screen for a muscarinic receptor using the Epic label-free system--a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors | Q39822254 | ||
The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? | Q39907784 | ||
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation | Q40234374 | ||
Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation | Q42084998 | ||
Screening for GPCR Ligands Using Surface Plasmon Resonance | Q42141178 | ||
G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. | Q42439529 | ||
Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. | Q42937057 | ||
The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. | Q42957555 | ||
Delineating the mode of action of adenosine A1 receptor allosteric modulators | Q43023574 | ||
Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae | Q43064157 | ||
Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor | Q43088304 | ||
Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. | Q46471412 | ||
Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. | Q51761046 | ||
Comparing label-free biosensors for pharmacological screening with cell-based functional assays. | Q51775180 | ||
P433 | issue | 2 | |
P921 | main subject | G protein-coupled receptor | Q38173 |
P304 | page(s) | e237-43 | |
P577 | publication date | 2013-01-01 | |
P1433 | published in | Drug discovery today. Technologies | Q27723323 |
P1476 | title | Allosteric modulation and functional selectivity of G protein-coupled receptors | |
P478 | volume | 10 |
Q47650573 | Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity |
Q28541837 | Chemical, target, and bioactive properties of allosteric modulation |
Q42650499 | Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor |
Q38211688 | Harnessing allostery: a novel approach to drug discovery |
Q38973739 | Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target |
Q42221343 | Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor |
Q37140411 | New paradigms in GPCR drug discovery. |
Q34372488 | Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). |
Q34027829 | Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor |
Q89539285 | Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1 |
Q38987183 | Structural studies of G protein-coupled receptors |
Q47597808 | Trends in GPCR drug discovery: new agents, targets and indications. |
Search more.